Hepatic, Hematologix Risks

  • Use with extreme caution in patients with renal impairment
  • Close monitoring of hematologic, renal and hepatic function
  • Review instructions thoroughly before administration

Monitoring data

  • Baseline electrolytes, hematological and renal status of patients should be determined.
  • Frequent monitoring of hematological(leucocyte and thrombocyte course), renal and hepatic status (alkaline phosphatase, SGOT, SGPT)of all patients.
  • Renal impairment may cause drug accumulation, thus blood concentrations and kidney function should be monitored during therapy.

Package inserts

Additional information

Updated: January 2018